TCRR Key Statistics, Chart & Performance
The current stock price of TCRR is 1.48 USD. In the past month the price decreased by -17.32%. In the past year, price decreased by -38.59%.
TCRR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TCRR. When comparing the yearly performance of all stocks, TCRR is a bad performer in the overall market: 69.05% of all stocks are doing better.
TCRR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TCRR. TCRR may be in some trouble as it scores bad on both profitability and health.
TCRR Financial Highlights
Over the last trailing twelve months TCRR reported a non-GAAP Earnings per Share(EPS) of -4.2. The EPS decreased by -49.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
TCRR Forecast & Estimates
12 analysts have analysed TCRR and the average price target is 5.86 USD. This implies a price increase of 295.87% is expected in the next year compared to the current price of 1.48.
TCRR Ownership
TCRR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.39 | 387.092B | ||
| AMGN | AMGEN INC | 17.06 | 198.053B | ||
| GILD | GILEAD SCIENCES INC | 17.07 | 185.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.48 | 116.409B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.91 | 80.573B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.82 | 43.76B | ||
| INSM | INSMED INC | N/A | 32.21B | ||
| NTRA | NATERA INC | N/A | 27.199B | ||
| BIIB | BIOGEN INC | 13.02 | 27.192B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.47 | 20.623B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TCRR
Company Profile
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. The company is headquartered in Cambridge, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2019-02-14. The firm's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The firm completed the Phase I portion of its Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510 and TC-520. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor. Its TC-520 is the Company’s TRuC-T cell targeting CD-70-expressing solid and liquid tumors which incorporates IL-15 pathway enhancements designed to improve T-cell persistence.
Company Info
TCR2 THERAPEUTICS INC
100 Binney St
Cambridge MASSACHUSETTS 02142 US
CEO: Garry E. Menzel
Employees: 58
Phone: 16179495200.0
TCR2 THERAPEUTICS INC / TCRR FAQ
What does TCRR do?
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. The company is headquartered in Cambridge, Massachusetts and currently employs 58 full-time employees. The company went IPO on 2019-02-14. The firm's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The firm completed the Phase I portion of its Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510 and TC-520. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor. Its TC-520 is the Company’s TRuC-T cell targeting CD-70-expressing solid and liquid tumors which incorporates IL-15 pathway enhancements designed to improve T-cell persistence.
What is the stock price of TCR2 THERAPEUTICS INC today?
The current stock price of TCRR is 1.48 USD. The price decreased by -5.73% in the last trading session.
Does TCRR stock pay dividends?
TCRR does not pay a dividend.
How is the ChartMill rating for TCR2 THERAPEUTICS INC?
TCRR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is TCRR stock listed?
TCRR stock is listed on the Nasdaq exchange.
What do analysts say about TCR2 THERAPEUTICS INC (TCRR) stock?
12 analysts have analysed TCRR and the average price target is 5.86 USD. This implies a price increase of 295.87% is expected in the next year compared to the current price of 1.48.
Can you provide the number of employees for TCR2 THERAPEUTICS INC?
TCR2 THERAPEUTICS INC (TCRR) currently has 58 employees.